Literature DB >> 34201583

PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings.

Falk Gühne1, Philipp Seifert1, Bernhard Theis2, Matthias Steinert3, Martin Freesmeyer1, Robert Drescher1.   

Abstract

PET/CT with prostate-specific membrane antigen (PSMA)-targeted tracers has been used in the diagnosis and staging of patients with clear cell renal cell carcinoma (ccRCC). For ccRCC primary tumors, PET parameters were shown to predict histologic grade and features. The aim of this study was to correlate PSMA PET/CT with histopathological findings in patients with metastatic recurrence of ccRCC. Patients with ccRCC who underwent PSMA-targeted PET/CT and subsequent histopathological evaluation of suspicious lesions were included. Specimens underwent immunohistochemical marking. Lesion diameter, volume and tracer uptake were correlated with the extent and intensity of molecular PSMA expression and with clinical findings. Twelve PET-positive lesions of nine patients were evaluated. Eleven ccRCC metastases and one prostate carcinoma were detected histopathologically. Molecular PSMA expression was detected in all lesions, which intensity and distribution did not correlate with PET parameters. PSMA-targeted PET/CT is a feasible tool for the evaluation of patients with ccRCC but cannot reliably predict histologic features of metastases. PSMA may also be expressed in malignant lesions other than ccRCC, leading to incidental detection of these tumors.

Entities:  

Keywords:  PET; PET/CT; PSMA; histopathology; renal cell carcinoma

Year:  2021        PMID: 34201583     DOI: 10.3390/diagnostics11071142

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  22 in total

Review 1.  Grading of renal cell carcinoma.

Authors:  Brett Delahunt; John N Eble; Lars Egevad; Hemamali Samaratunga
Journal:  Histopathology       Date:  2019-01       Impact factor: 5.087

2.  (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Authors:  Emre Demirci; Meltem Ocak; Levent Kabasakal; Clemens Decristoforo; Zübeyir Talat; Metin Halaç; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-23       Impact factor: 9.236

3.  PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma.

Authors:  L M Mittlmeier; M Unterrainer; A Todica; C C Cyran; S Rodler; P Bartenstein; C G Stief; H Ilhan; M Staehler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-11       Impact factor: 9.236

4.  68Ga-PSMA PET/CT and 18F-FDG PET/CT in Renal Cell Carcinoma.

Authors:  Ew-Jun Chen; Teik Hin Tan; Ming Tsuey Chew; Ping Ching Chye
Journal:  Clin Nucl Med       Date:  2020-07       Impact factor: 7.794

5.  [Study on the pathological grade in the primary and distant metastatic lesions of renal cell carcinoma].

Authors:  T Onishi; Y Ohishi; N Iizuka; H Makino
Journal:  Hinyokika Kiyo       Date:  1995-12

Review 6.  Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Authors:  Chiara Pozzessere; Maria Bassanelli; Anna Ceribelli; Sazan Rasul; Shuren Li; John O Prior; Francesco Cicone
Journal:  Curr Urol Rep       Date:  2019-10-11       Impact factor: 3.092

7.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

Authors:  Angelo Baccala; Linda Sercia; Jianbo Li; Warren Heston; Ming Zhou
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

8.  Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Authors:  Steven P Rowe; Michael A Gorin; Hans J Hammers; M Som Javadi; Hazem Hawasli; Zsolt Szabo; Steve Y Cho; Martin G Pomper; Mohamad E Allaf
Journal:  Ann Nucl Med       Date:  2015-08-19       Impact factor: 2.668

9.  Effects of bulbus Fritillaria water extract on blood pressure and renal functions in the L-NAME-induced hypertensive rats.

Authors:  Dae Gill Kang; Eun Jin Sohn; Yun Mi Lee; An Sook Lee; Jong Hyun Han; Tai Yo Kim; Ho Sub Lee
Journal:  J Ethnopharmacol       Date:  2004-03       Impact factor: 4.360

Review 10.  Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings.

Authors:  Felipe de Galiza Barbosa; Marcelo Araujo Queiroz; Rafael Fernandes Nunes; Larissa Bastos Costa; Elaine Caroline Zaniboni; José Flavio Gomes Marin; Giovanni Guido Cerri; Carlos Alberto Buchpiguel
Journal:  Cancer Imaging       Date:  2020-03-14       Impact factor: 3.909

View more
  6 in total

1.  Application of PET/CT in Preoperative Evaluation and Diagnosis of Gastric Cancer.

Authors:  Xin Zhou; Yongpeng Zhang; Xipeng Zhao; Lin Zhou; Xia Jia; Libo Pan
Journal:  Comput Math Methods Med       Date:  2022-04-04       Impact factor: 2.238

Review 2.  PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature.

Authors:  Stijn Muselaers; Selcuk Erdem; Riccardo Bertolo; Alexandre Ingels; Önder Kara; Nicola Pavan; Eduard Roussel; Angela Pecoraro; Michele Marchioni; Umberto Carbonara; Laura Marandino; Daniele Amparore; Riccardo Campi
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

Review 3.  Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.

Authors:  Luca Urso; Angelo Castello; Giovanni Christian Rocca; Federica Lancia; Stefano Panareo; Corrado Cittanti; Licia Uccelli; Luigia Florimonte; Massimo Castellani; Carmelo Ippolito; Antonio Frassoldati; Mirco Bartolomei
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-25       Impact factor: 4.322

Review 4.  PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?

Authors:  Alessio Rizzo; Sara Dall'Armellina; Daniele Antonio Pizzuto; Germano Perotti; Luca Zagaria; Valerio Lanni; Giorgio Treglia; Manuela Racca; Salvatore Annunziata
Journal:  Cancers (Basel)       Date:  2022-08-21       Impact factor: 6.575

5.  Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma.

Authors:  Cristian Udovicich; Jason Callahan; Mathias Bressel; Wee Loon Ong; Marlon Perera; Ben Tran; Arun Azad; Shankar Haran; Daniel Moon; Sarat Chander; Mark Shaw; Renu Eapen; Jeremy Goad; Nathan Lawrentschuk; Declan G Murphy; Michael Hofman; Shankar Siva
Journal:  Eur Urol Open Sci       Date:  2022-08-29

6.  Differences in Distribution and Detection Rate of the [68Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11-Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer.

Authors:  Falk Gühne; Stefanie Radke; Thomas Winkens; Christian Kühnel; Julia Greiser; Philipp Seifert; Robert Drescher; Martin Freesmeyer
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.